Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection

Human Genomics

Volumn 7, Issue 1, 2013, Pages

  Lanara, Zoi ^a,b   Giannopoulou, Efstathia ^b   Fullen, Marta ^c   Kostantinopoulos, Evangelos ^b   Nebel, Jean Christophe ^c   Kalofonos, Haralabos P ^b   Patrinos, George P ^b   Pavlidis, Cristiana ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PATRAS   (Greece)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Alleles; Association; Cancer; Clustering; Gene; Interaction; Meta analysis; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN P53; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A; XERODERMA PIGMENTOSUM GROUP D PROTEIN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANCESTRY GROUP; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; COMPARATIVE STUDY; DISEASE CLASSIFICATION; EARLY CANCER; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE PHENOTYPE CORRELATION; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; META ANALYSIS; MOUTH CANCER; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; CLASSIFICATION; EARLY DIAGNOSIS; EPISTASIS; GENETICS; HUMAN GENOME; META ANALYSIS (TOPIC); NEOPLASMS; TUMOR GENE;

EARLY DETECTION OF CANCER; EPISTASIS, GENETIC; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901066432     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-7-14     Document Type: Article

References (217)

1. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK: Genetic pathways and mutation profiles of human cancers: site- and exposurespecific patterns. Carcinogenesis 2007, 28(9):1851-1858. (Pubitemid 47504878)
2. Dutt A, Beroukhim R: Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 2007, 19(1):43-49. (Pubitemid 44885599)
3. Chung CC, Chanock SJ: Current status of genome-wide association studies in cancer. Hum Genet 2011, 130(1):59-78.
4. Rae JM, Skaar TC, Hilsenbeck SG, Oesterreich S: The role of single nucleotide polymorphisms in breast cancer metastasis. Breast Cancer Res 2008, 10(1):301.
5. Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD Jr, Siniard A, Duggan D, Thomas DC, WECARE Study Collaborative Group, Concannon P: Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the women's environment, cancer, and radiation epidemiology (WECARE) study. Breast Cancer Res 2011, 13(6):R114.
6. Inaki K, Liu ET: Structural mutations in cancer: mechanistic and functional insights. Trends Genet 2012, 28(11):550-559.
7. You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012, 22(1):9-20.
8. Lopez-Lazaro M: A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med 2010, 16(3-4):144-153.
9. Rasmussen MD, Deshpande MS, Karypis G, Johnson J, Crow JA, Retzel EF: wCLUTO: a Web-enabled clustering toolkit. Plant Physiol 2003, 133(2):510-516.
10. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, von Mering C: The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, 39(Database issue):D561-D568.
11. Search Tool for the Retrieval of Interacting Genes/Proteins. www.string-db.org.
12. Jiang Z, Li C, Xu Y, Cai S, Wang X: Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat 2010, 123(1):203-212.
13. Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, Mao C, Chen B, Zhan P, Yuan H, Hu X-C: XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Res Treat 2010, 124(1):229-235.
14. Wang HC, Liu CS, Wang CH, Tsai RY, Tsai CW, Wang RF, Chang CH, Chen YS, Chiu CF, Bau DT, Huang CY: Significant association of XPD Asp312Asn polymorphism with breast cancer in Taiwanese patients. Chin J Physiol 2010, 53(2):130-135.
15. Han W, Kim KY, Yang SJ, Noh DY, Kang D, Kwack K: SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population. Cancer 2012, 118(3):594-602.
16. Hussien YM, Gharib AF, Awad HA, Karam RA, Elsawy WH: Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Mol Biol Rep 2012, 39(2):1895-1901.
17. Yin J, Vogel U, Wang C, Liang D, Ma Y, Wang H, Yue L, Liu D, Ma J, Sun X: Hapmap-based evaluation of ERCC2, PPP1R13L, and ERCC1 and lung cancer risk in a Chinese population. Environ Mol Mutagen 2012, 53(3):239-245.
18. Yao L, Qiu LX, Yu L, Yang Z, Yu XJ, Zhong Y, Hu XC: The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects. Breast Cancer Res Treat 2010, 123(1):227-231.
19. Zhang J, Gu SY, Zhang P, Jia Z, Chang JH: ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians. Eur J Cancer 2010, 46(13):2479-2484.
20. Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, Song Y: ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. J Thorac Oncol 2010, 5(9):1337-1345.
21. Yin J, Vogel U, Ma Y, Qi R, Wang H, Yue L, Liang D, Wang C, Li X, Song T: HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population. Mutat Res 2011, 713(1-2):1-7.
22. Christiani DC: ERCC2/XPD polymorphisms and lung cancer risk. J Thorac Oncol 2011, 6(1):233. author reply 233-235.
23. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH: The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol 2011, 28(3):655-660.
24. Sergentanis TN, Economopoulos KP: Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep 2011, 38(8):4955-4963.
25. Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES: Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 2009, 28(15):1812-1820.
26. Miyashita H, Mori S, Tanda N, Nakayama K, Kanzaki A, Sato A, Morikawa H, Motegi K, Takebayashi Y, Fukumoto M: Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue. Oncol Rep 2001, 8(5):1133-1138.
27. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 2000, 1497(2):186-196. (Pubitemid 30618830)
28. Musgrove EA, Hui R, Sweeney KJ, Watts CK, Sutherland RL: Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 1996, 1(2):153-162.
29. Sutherland RL, Hamilton JA, Sweeney KJ, Watts CK, Musgrove EA: Expression and regulation of cyclin genes in breast cancer. Acta Oncol 1995, 34(5):651-656.
30. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, Taneja NK, Inoue K: MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009, 9(5):423-440.
31. Yang C, Ionescu-Tiba V, Burns K, Gadd M, Zukerberg L, Louis DN, Sgroi D, Schmidt EV: The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. Am J Pathol 2004, 164(3):1031-1038. (Pubitemid 38235484)
32. Zhou GW, Hu J, Li Q: CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis. World J Gastroenterol 2010, 16(23):2949-2953.
33. Silva TD, Felipe AV, Pimenta CA, Barao K, Forones NM: CYP2E1 RsaI and 96-bp insertion genetic polymorphisms associated with risk for colorectal cancer. Genet Mol Res 2012, 11(3):3138-3145.
34. Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA: Role of CYP2E1 genotypes in susceptibility to colorectal cancer in the Kashmiri population. Hum Genomics 2011, 5(6):530-537.
35. Yang H, Zhou Y, Zhou Z, Liu J, Yuan X, Matsuo K, Takezaki T, Tajima K, Cao J: A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism rs671 of ALDH2 of alcohol metabolizing enzymes are associated with colorectal cancer in a southwestern Chinese population. Cancer Epidemiol Biomarkers Prev 2009, 18(9):2522-2527.
36. Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, Colman H, Le Houerou C, Le Neel T, Bourdon J, Faroux R, Ollivry J, Lafraise B, Chupin LD, Bézieau S: Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 2007, 16(7):1460-1467. (Pubitemid 47076879)
37. Chen K, Jin MJ, Fan CH, Song L, Jiang QT, Yu WP, Ma XY, Yao KY: A case-control study on the association between genetic polymorphisms of metabolic enzymes and the risk of colorectal cancer. Zhonghua Liu Xing Bing Xue Za Zhi 2005, 26(9):659-664.
38. van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, Nagengast FM, Peters WH: Role of epoxide hydrolase, NAD(P)H: quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 2006, 593(1-2):39-49. (Pubitemid 43113361)
39. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F: A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005, 15(8):535-546. (Pubitemid 41044239)
40. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA: Red meat intake, doneness, polymorphisms in genes that encode carcinogen- metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17(11):3098-3107.
41. Chen J, Huang XF: The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009, 8(14):1313-1317.
42. Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, Feng G, He L, Qin S: The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a metaanalysis based on 21 case-control studies. BMC Cancer 2010, 10:575.
43. Lu D, Yu X, Du Y: Meta-analyses of the effect of cytochrome P450 2E1 gene polymorphism on the risk of head and neck cancer. Mol Biol Rep 2011, 38(4):2409-2416.
44. Garcia SM, Curioni OA, de Carvalho MB, Gattas GJ: Polymorphisms in alcohol metabolizing genes and the risk of head and neck cancer in a Brazilian population. Alcohol Alcohol 2010, 45(1):6-12.
45. Economopoulos KP, Sergentanis TN: GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. Eur J Cancer 2010, 46(9):1617-1631.
46. Ebrahimkhani S, Asgharian AM, Nourinaier B, Ebrahimkhani K, Vali N, Abbasi F, Zali MR: Association of GSTM1, GSTT1, GSTP1 and CYP2E1 single nucleotide polymorphisms with colorectal cancer in Iran. Pathol Oncol Res 2012, 18(3):651-656.
47. Sameer AS, Qadri Q, Siddiqi MA: GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. DNA Cell Biol 2012, 31(1):74-79.
48. Wang J, Joshi AD, Corral R, Siegmund KD, Marchand LL, Martinez ME, Haile RW, Ahnen DJ, Sandler RS, Lance P, Stern MC: Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. Int J Cancer 2012, 130(8):1898-1907.
49. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schonfels W, Hampe J, Schafmayer C, Volzke H, Frank B, Brenner H, Försti A, Hemminki K, Chang-Claude J: Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011, 18(2):265-276.
50. Jones BA, Christensen AR, Wise JP Sr, Yu H: Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. Cancer Epidemiol 2009, 33(3-4):249-256.
51. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, Tveit KM, Hoff G, Kure EH: Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer 2007, 7:228.
52. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ: Genetic polymorphisms in xenobiotic clearance genes and their influence on disease expression in hereditary nonpolyposis colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2307-2310. (Pubitemid 44877061)
53. Romero RZ, Morales R, Garcia F, Huarriz M, Bandres E, De la Haba J, Gomez A, Aranda E, Garcia-Foncillas J: Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 2006, 16(3):497-503.
54. Probst-Hensch NM, Sun CL, Van Den Berg D, Ceschi M, Koh WP, Yu MC: The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese health study. Carcinogenesis 2006, 27(12):2475-2482. (Pubitemid 44884106)
55. Gaustadnes M, Orntoft TF, Jensen JL, Torring N: Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat 2006, 27(2):187-194. (Pubitemid 43238034)
56. Yu KD, Di GH, Fan L, Chen AX, Yang C, Shao ZM: Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat 2010, 122(2):483-488.
57. Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, Min ZC, Tao J, Li PC, Zhang W, Wu HF, Zhang ZD, Wang ZJ, Hua LX, Feng NH, Wang XR: IL-6-174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 2011, 38(4):2589-2596.
58. Dong X, Wu J, Liang P, Li J, Yuan L, Liu X: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res 2010, 41(2):125-133.
59. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y: Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 2012, 12:137.
60. Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, Canzian F, Kaaks R, Boeing H, Meidtner K, Trichopoulou A, Laglou P, Vineis P, Panico S, Palli D, Grioni S, Tumino R, Lund E, Bueno-de-Mesquita HB, Numans ME, Peeters PH, Ramon Quirós J, Sánchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Hallmans G, Stenling R, et al: Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett 2011, 311(1):85-95.
61. Qi X, Ma X, Yang X, Fan L, Zhang Y, Zhang F, Chen L, Zhou Y, Jiang J: Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat 2010, 123(2):499-506.
62. Qiu LX, Zhang J, Li WH, Zhang QL, Yu H, Wang BY, Wang LP, Wang JL, Wang HJ, Liu XJ, Luo ZG, Wu XH: Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility. Mol Biol Rep 2011, 38(4):2295-2299.
63. Perel'muter VM, Zav'ialova MV, Vtorushin SV, Slonimskaia EM, Kritskaia NG, Garbukov E, Litviakov NV, Stakheeva MN, Babyshkina NN, Malinovskaia EA, Denisov EV, Grigor'eva ES, Nazarenko MS, Sennikov SV, Goreva EP, Kozlov VA, Voevoda MI, Maksimov VN, Beliavskaia VA, Cherdyntseva NV: Genetic and clinical and pathological characteristics of breast cancer in premenopausal and postmenopausal women. Adv Gerontol 2008, 21(4):643-653.
64. Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Feigelson HS, Thun MJ, Calle EE: Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 2007, 16(6):1140-1147. (Pubitemid 46984950)
65. Qiu LX, Mao C, Yao L, Yu KD, Zhan P, Chen B, Liu HG, Yuan H, Zhang J, Xue K, Hu XC: XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2010, 122(2):489-493.
66. Chen Y, Pei J: Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial. Breast Cancer Res Treat 2011, 125(2):495-504.
67. Qi X, Zhang F, Yang X, Fan L, Zhang Y, Chen L, Zhou Y, Chen X, Zhong L, Jiang J: Transforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studies. Breast Cancer Res Treat 2010, 122(1):273-279.
68. Huang Y, Hao Y, Li B, Xie J, Qian J, Chao C, Yu L: Lack of significant association between TGF-beta1-590C/T polymorphism and breast cancer risk: a meta-analysis. Med Oncol 2011, 28(2):424-428.
69. Woo SU, Park KH, Woo OH, Yang DS, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH: Association of a TGF-beta1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 124(2):481-485.
70. Gu D, Zhuang L, Huang H, Cao P, Wang D, Tang J, Chen J: TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls. Breast Cancer Res Treat 2010, 123(3):857-861.
71. Wei BB, Xi B, Wang R, Bai JM, Chang JK, Zhang YY, Yoneda R, Su JT, Hua LX: TGFbeta1 T29C polymorphism and cancer risk: a meta-analysis based on 40 case-control studies. Cancer Genet Cytogenet 2010, 196(1):68-75.
72. Ma X, Chen C, Xiong H, Li Y: Transforming growth factorbeta1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat 2010, 124(2):453-457.
73. Huang Y, Li B, Qian J, Xie J, Yu L: TGF-beta1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects. Breast Cancer Res Treat 2010, 123(3):863-868.
74. Qiu LX, Yao L, Mao C, Chen B, Zhan P, Xue K, Zhang J, Yuan H, Hu XC: TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects. Breast Cancer Res Treat 2010, 123(2):563-567.
75. Radisky DC, Hartmann LC: Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia 2009, 14(2):181-191.
76. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE: Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 2010, 5(3):e9832.
77. Zheng W: Genetic polymorphisms in the transforming growth factorbeta signaling pathways and breast cancer risk and survival. Methods Mol Biol 2009, 472:265-277.
78. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L: Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 2010, 31(4):643-647.
79. Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, Qin H: No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 2011, 125(1):201-205.
80. Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK: Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors. Ann Surg Oncol 2004, 11(12):1045-1055. (Pubitemid 40486650)
81. Rebbeck TR: Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999, 86(11 Suppl):2493-2501. (Pubitemid 30007532)
82. Rossner P Jr, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 2009, 13(9B):3847-3857.
83. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 2009, 21(6):1611-1619.
84. Palanca Suela S, Esteban Cardenosa E, Barragan Gonzalez E, de Juan Jimenez I, Chirivella Gonzalez I, Segura Huerta A, Guillen Ponce C, Montalar Salcedo J, Martinez de Duenas E, Castel Sanchez V, Bolufer Gilabert P, Group for Assessment of Hereditary Cancer of Valencia Community: CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Breast Cancer Res Treat 2010, 119(1):87-93.
85. Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V, Russo A: Breast cancer genome-wide association studies: there is strength in numbers. Oncogene 2012, 31(17):2121-2128.
86. Cherdyntseva NV, Denisov EV, Litviakov NV, Maksimov VN, Malinovskaya EA, Babyshkina NN, Slonimskaya EM, Voevoda MI, Choinzonov EL: Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol 2012, 31(3):306-316.
87. Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T: High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 2012, 106(2):397-404.
88. Mathoulin-Portier MP, Viens P, Cowen D, Bertucci F, Houvenaeghel G, Geneix J, Puig B, Bardou VJ, Jacquemier J: Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin. Oncol Rep 2000, 7(3):675-680.
89. Blackburn AC, Jerry DJ: Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Res 2002, 4(3):101-111. (Pubitemid 34520735)
90. Bennett CN, Green JE: Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol Pathol 2010, 38(1):88-95.
91. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G: A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20(1):79-91.
92. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J: A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008, 47(4):600-607. (Pubitemid 351878460)
93. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM: p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011, 13(1):R7.
94. Besaratinia A, Pfeifer GP: Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J 2010, 24(8):2612-2619.
95. Jiang DK, Ren WH, Yao L, Wang WZ, Peng B, Yu L: Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 2010, 76(3):765-767. e761.
96. Burger M, Burger SJ, Denzinger S, Wild PJ, Wieland WF, Blaszyk H, Obermann EC, Stoehr R, Hartmann A: Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol 2006, 50(4):770-775. discussion 776.
97. Zuiverloon TC, Abas CS, van der Keur KA, Vermeij M, Tjin SS, van Tilborg AG, Busstra M, Zwarthoff EC: In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report. BMC Urol 2010, 10:5.
98. Kompier LC, van Tilborg AA, Zwarthoff EC: Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications. Urol Oncol 2010, 28(1):91-96.
99. Jarmalaite S, Andrekute R, Scesnaite A, Suziedelis K, Husgafvel-Pursiainen K, Jankevicius F: Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J Cancer Res Clin Oncol 2010, 136(6):847-854.
100. Lin HY, Huang CH, Yu TJ, Wu WJ, Yang MC, Lung FW: p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep 2012, 27(4):1193-1199.
101. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S: TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and metaanalysis. Cancer Epidemiol Biomarkers Prev 2010, 19(7):1840-1847.
102. Economopoulos KP, Sergentanis TN, Zagouri F, Zografos GC: Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. Onkologie 2010, 33(12):666-674.
103. Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC: TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 2011, 38(8):4847-4853.
104. Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC: Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006, 118(7):1790-1797. (Pubitemid 43376445)
105. Zhang Y, Liu L, Tang Y, Chen C, Wang Q, Xu J, Yang C, Miao X, Wei S, Chen J, Nie S: Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study. Mol Biol Rep 2012, 39(10):9661-9668.
106. Lopez I, PO L, Tucci P, Alvarez-Valin F, AC R, Marin M: Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene 2012, 499(1):81-87.
107. Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, Weller C, Cohen E, Roberts H, Keskey B, Petras RE, Crawford NP, Galandiuk S: Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat 2012, 33(3):551-560.
108. Aizat AA, Shahpudin SN, Mustapha MA, Zakaria Z, Sidek AS, Abu Hassan MR, Ankathil R: Association of Arg72Pro of P53 polymorphism with colorectal cancer susceptibility risk in Malaysian population. Asian Pac J Cancer Prev 2011, 12(11):2909-2913.
109. Wang B, Wang D, Zhang D, Li A, Liu D, Liu H, Jin H: Pro variant of TP53 Arg72Pro contributes to esophageal squamous cell carcinoma risk: evidence from a meta-analysis. Eur J Cancer Prev 2010, 19(4):299-307.
110. Zhao Y, Wang F, Shan S, Qiu X, Li X, Jiao F, Wang J, Du Y: Genetic polymorphism of p53, but not GSTP1, is association with susceptibility to esophageal cancer risk - a meta-analysis. Int J Med Sci 2010, 7(5):300-308.
111. Bashash M, Yavari P, Hislop TG, Shah A, Sadjadi A, Babaei M, Le N, Brooks-Wilson A, Malekzadeh R, Bajdik C: Comparison of two diverse populations, British Columbia, Canada, and Ardabil, Iran, indicates several variables associated with gastric and esophageal cancer survival. J Gastrointest Cancer 2011, 42(1):40-45.
112. Duenas M, Santos M, Aranda JF, Bielza C, Martinez-Cruz AB, Lorz C, Taron M, Ciruelos EM, Rodriguez-Peralto JL, Martin M, Larrañaga P, Dahabreh J, Stathopoulos GP, Rosell R, Paramio JM, García-Escudero R: Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One 2012, 7(8):e42494.
113. Perez-Morales R, Mendez-Ramirez I, Castro-Hernandez C, Martinez-Ramirez OC, Gonsebatt ME, Rubio J: Polymorphisms associated with the risk of lung cancer in a healthy Mexican Mestizo population: application of the additive model for cancer. Genet Mol Biol 2011, 34(4):546-552.
114. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE: Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007, 67(17):8065-8080. (Pubitemid 47395141)
115. Campling BG, el-Deiry WS: Clinical implications of p53 mutations in lung cancer. Methods Mol Med 2003, 75:53-77.
116. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462(7269):104-107.
117. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86(19):1458-1462. (Pubitemid 24317587)
118. Jiang DK, Yao L, Ren WH, Wang WZ, Peng B, Yu L: TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis. Med Oncol 2011, 28(4):1129-1135.
119. Chen MB, Li C, Shen WX, Guo YJ, Shen W, Lu PH: Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls. Mol Biol Rep 2011, 38(7):4687-4695.
120. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61(15):5736-5740. (Pubitemid 32769088)
121. Eriksson L, Ahluwalia M, Spiewak J, Lee G, Sarma DS, Roomi MJ, Farber E: Distinctive biochemical pattern associated with resistance of hepatocytes in hepatocyte nodules during liver carcinogenesis. Environ Health Perspect 1983, 49:171-174. (Pubitemid 13098353)
122. Volm M, Koomagi R, Rittgen W: Clinical implications of cyclins, cyclindependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 1998, 79(3):294-299. (Pubitemid 28262217)
123. Anayama T, Furihata M, Takeuchi T, Sonobe H, Sasaguri S, Matsumoto M, Ohtsuki Y: Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro. Int J Oncol 2001, 18(1):151-155.
124. Buschges R, Weber RG, Actor B, Lichter P, Collins VP, Reifenberger G: Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999, 9(3):435-442. discussion 432-433.
125. Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE: Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009, 15(17):5338-5349.
126. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T: Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001, 165(2):171-177. (Pubitemid 32244174)
127. Uematsu F: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to lung cancer-relevance to smoking. Nihon Rinsho 1996, 54(2):513-517.
128. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT, Burke MD: Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol 1995, 76(4):271-276.
129. Hu YY, Yuan H, Jiang GB, Chen N, Wen L, Leng WD, Zeng XT, Niu YM: Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects. PLoS One 2012, 7(4):e35220.
130. Yuan H, Niu YM, Wang RX, Li HZ, Chen N: Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res 2011, 10(4):3356-3364.
131. Kumar A, Pant MC, Singh HS, Khandelwal S: Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population. Mutat Res 2012, 729(1-2):24-34.
132. Clapper ML: Genetic polymorphism and cancer risk. Curr Oncol Rep 2000, 2(3):251-256.
133. Likhin FA, Bartnovskii AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma. Urologiia 2005, 4:12-15.
134. Zhang Z, Liu W, Jia X, Gao Y, Hemminki K, Lindholm B: Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta 2004, 342(1-2):137-143. (Pubitemid 38352922)
135. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004, 4(1):66-72. (Pubitemid 38256607)
136. Petra BG, Janez J, Vita D: Gene-gene interactions in the folate metabolic
137. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS: Prognostic significance of folate metabolism polymorphisms for lung cancer. Br J Cancer 2007, 97(2):247-252. (Pubitemid 47057467)
138. Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, Garcia-Closas R, Silverman D, Chanock S, Welch R, Tardón A, Serra C, Carrato A, Dosemeci M, García-Closas M: Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer 2007, 120(11):2452-2458. (Pubitemid 46642134)
139. Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, Albertsen H, Potter JD, Samowitz WS: Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis 2007, 28(8):1672-1679. (Pubitemid 47303944)
140. Weiner AS, Beresina OV, Voronina EN, Voropaeva EN, Boyarskih UA, Pospelova TI, Filipenko ML: Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin's lymphoma. Leuk Res 2011, 35(4):508-515.
141. Lee KM, Lan Q, Kricker A, Purdue MP, Grulich AE, Vajdic CM, Turner J, Whitby D, Kang D, Chanock S, Rothman N, Armstrong BK: One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet 2007, 122(5):525-533. (Pubitemid 350148964)
142. Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, Saito T, Sato S, Ueda R, Tajima K: One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study. Cancer Sci 2007, 98(9):1439-1446. (Pubitemid 47241768)
143. Kim SH, Lee SH, Choi YL, Wang LH, Park CK, Shin YK: Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence. Histol Histopathol 2008, 23(12):1439-1452.
144. Gemma A, Uematsu K, Hagiwara K, Takenoshita S, Kudoh S: Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy. Gan To Kagaku Ryoho 2000, 27(8):1253-1259.
145. Jonson T, Albrechtsson E, Axelson J, Heidenblad M, Gorunova L, Johansson B, Hoglund M: Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int J Oncol 2001, 19(1):71-81.
146. Franzen P, Ichijo H, Miyazono K: Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res 1993, 207(1):1-7. (Pubitemid 23192157)
147. Maggio-Price L, Treuting P, Bielefeldt-Ohmann H, Seamons A, Drivdahl R, Zeng W, Lai L, Huycke M, Phelps S, Brabb T, Iritani BM: Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer. Am J Pathol 2009, 174(1):317-329.
148. Hirshfield KM, Rebbeck TR, Levine AJ: Germline mutations and polymorphisms in the origins of cancers in women. J Oncol 2010, 2010:297671.
149. Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL: Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther 2010, 9(2):461-470.
150. Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Secord AA, Murphy SK, Iversen E, Marks JR, Berchuck A: Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer 2010, 10:237.
151. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y: Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012, 61(3):344-353.
152. Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C, Myers JN: Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 2011, 17(21):6658-6670.
153. Furth PA, Cabrera MC, Diaz-Cruz ES, Millman S, Nakles RE: Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models. Ann N Y Acad Sci 2011, 1229:147-155.
154. de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ, Peters GJ, Ravindranath Y, Pieters R, Lindemans J: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005, 106(2):717-720. (Pubitemid 40981271)
155. Durfort T, Tkach M, Meschaninova MI, Rivas MA, Elizalde PV, Venyaminova AG, Schillaci R, Francois JC: Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One 2012, 7(1):e29213.
156. Calogero RA, Cordero F, Forni G, Cavallo F: Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 2007, 9(4):211.
157. Schiff R, Osborne CK: Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 2005, 7(5):205-211. (Pubitemid 41387432)
158. Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, Fischer JR, Lorenzoni M, Givel JC, Odartchenko N: Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer 1992, 28A(11):1894-1899.
159. Yu C, Yao Z, Jiang Y, Keller ET: Prostate cancer stem cell biology. Minerva Urol Nefrol 2012, 64(1):19-33.
160. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L: Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 2010, 25(4):371-379.
161. Zhang YM, Cao C, Liang K: Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol 2010, 34(2):150-156.
162. Willmarth NE, Ethier SP: Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2008, 13(2):171-179.
163. Guise TA: Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009, 23(18):2117-2123.
164. Lacroix M, Body JJ: Regulation of c-fos and c-jun expression by calcitonin in human breast cancer cells. Calcif Tissue Int 1997, 60(6):513-519. (Pubitemid 27230010)
165. Chen MB, Wu XY, Shen W, Wei MX, Li C, Cai B, Tao GQ, Lu PH: Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects. Breast Cancer Res Treat 2011, 126(1):177-183.
166. Gu D, Wang M: VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls. Breast Cancer Res Treat 2011, 125(2):489-493.
167. Qiu LX, Wang K, Yang S, Mao C, Zhao L, Yao L, Zhang J, Zhang QL, Sun S, Xue K: Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility. Mol Biol Rep 2011, 38(7):4491-4494.
168. Yang DS, Park KH, Woo OH, Woo SU, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, Seo JH: Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011, 125(3):849-853.
169. Xu B, Li JM, Tong N, Tao J, Li PC, Song NH, Zhang W, Wu HF, Feng NH, Hua LX: VEGFA +936C>T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet 2010, 198(1):7-14.
170. Liu X, Wang Z, Yu J, Lei G, Wang S: Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat 2010, 124(3):821-825.
171. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, DiAugustine RP, Barrett JC, Afshari CA, Dunn SE: Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002, 4(3):204-217. (Pubitemid 34525252)
172. Cao C, Ying T, Fang JJ, Sun SF, Lv D, Chen ZB, Ma HY, Yu YM, Ding QL, Shu LH, Deng Z-C: Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects. Med Oncol 2011, 28(4):1169-1175.
173. Xue H, Lin B, Ni P, Xu H, Huang G: Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010, 25(10):1604-1617.
174. Gao LB, Pan XM, Jia J, Liang WB, Rao L, Xue H, Zhu Y, Li SL, Lv ML, Deng W, Chen TY, Wei YG, Zhang L: IL-8-251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer 2010, 46(8):1333-1343.
175. Liu L, Zhuang W, Wang C, Chen Z, Wu XT, Zhou Y: Interleukin-8-251 A/T gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiological studies. Cytokine 2010, 50(3):328-334.
176. Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, Zhang Z, Wang X, Yu L: Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis 2010, 25(1):41-48.
177. Wysoczynski M, Ratajczak MZ: Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 2009, 125(7):1595-1603.
178. Xie Y, Zhang H, Sheng W, Xiang J, Ye Z, Yang J: Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Lett 2008, 271(1):105-116.
179. Gao Y, Cao Y, Tan A, Liao C, Mo Z, Gao F: Glutathione S-transferase M1 polymorphism and sporadic colorectal cancer risk: an updating metaanalysis and HuGE review of 36 case-control studies. Ann Epidemiol 2010, 20(2):108-121.
180. Lu S, Wang Z, Cui D, Liu H, Hao X: Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: a meta-analysis involving 34,658 subjects. Breast Cancer Res Treat 2011, 125(1):253-259.
181. Qiu LX, Yuan H, Yu KD, Mao C, Chen B, Zhan P, Xue K, Zhang J, Hu XC: Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat 2010, 121(3):703-708.
182. Singh V, Parmar D, Singh MP: Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? Cancer Invest 2008, 26(8):769-783.
183. Curran JE, Weinstein SR, Griffiths LR: Polymorphisms of glutathione Stransferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett 2000, 153(1-2):113-120. (Pubitemid 30209852)
184. Economopoulos KP, Sergentanis TN, Vlahos NF: Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer 2010, 20(5):732-737.
185. Zeng FF, Liu SY, Wei W, Yao SP, Zhu S, Li KS, Wan G, Zhang HT, Zhong M, Wang BY: Genetic polymorphisms of glutathione S-transferase T1 and bladder cancer risk: a meta-analysis. Clin Exp Med 2010, 10(1):59-68.
186. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, Colt JS, Kida M, Jones MA, Schned AR, Cherala SS, Chanock SJ, Cantor KP, Silverman DT, Rothman N: GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011, 32(2):182-189.
187. Tsukuda M, Nagahara T, Yago T, Matsuda H, Yanoma S: Production of granulocyte colony-stimulating factor by head and neck carcinomas. Biotherapy 1993, 6(3):183-187. (Pubitemid 23341320)
188. Lagadec PF, Saraya KA, Balkwill FR: Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int J Cancer 1991, 48(2):311-317.
189. Enzmann V, Faude F, Kohen L, Wiedemann P: Secretion of cytokines by human choroidal melanoma cells and skin melanoma cell lines in vitro. Ophthalmic Res 1998, 30(3):189-194. (Pubitemid 28242950)
190. Kimura F, Nakamura Y, Sato K, Wakimoto N, Kato T, Tahara T, Yamada M, Nagata N, Motoyoshi K: Cyclic change of cytokines in a patient with cyclic thrombocytopenia. Br J Haematol 1996, 94(1):171-174. (Pubitemid 26232562)
191. Reinhold D, Bank U, Buhling F, Lendeckel U, Ulmer AJ, Flad HD, Ansorge S: Transforming growth factor-beta 1 (TGF-beta 1) inhibits DNA synthesis of PWM-stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokine 1994, 6(4):382-388. (Pubitemid 24263883)
192. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ: Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007, 56(3):371-379. (Pubitemid 46035905)
193. Freedman RS, Deavers M, Liu J, Wang E: Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2004, 2(1):23.
194. Jarnicki A, Putoczki T, Ernst M: Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell division 2010, 5:14.
195. Rundhaug JE, Fischer SM: Molecular mechanisms of mouse skin tumor promotion. Cancers 2010, 2(2):436-482.
196. Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, Sturzl M, Gunzburg WH, Hohenadl C: Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers. J Biomed Biotechnol 2009, 2009:437284.
197. Hiss D: Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. Journal of Oncology 2012, 2012:737981.
198. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837.
199. Chen Z, Yan B, Van Waes C: The role of the NF-kappaB transcriptome and proteome as biomarkers in human head and neck squamous cell carcinomas. Biomark Med 2008, 2(4):409-426.
200. Shimada Y, Imamura M: Prognostic factors for esophageal cancer-from the viewpoint of molecular biology. Gan To Kagaku Ryoho 1996, 23(8):972-981. (Pubitemid 26264600)
201. Ziober BL, Turner MA, Palefsky JM, Banda MJ, Kramer RH: Type I collagen degradation by invasive oral squamous cell carcinoma. Oral Oncol 2000, 36(4):365-372. (Pubitemid 30427258)
202. Nuovo GJ: In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 1997, 71(6):1056-1060. (Pubitemid 27252890)
203. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW: Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer 2001, 93(6):781-785. (Pubitemid 32756746)
204. Stachel D, Albert M, Meilbeck R, Kreutzer B, Haas RJ, Schmid I: Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL). Eur J Med Res 2006, 11(3):102-113.
205. Melinceanu L, Sarafoleanu C, Lerescu L, Tucureanu C, Caras I, Salageanu A: Impact of smoking on the immunological profile of patients with laryngeal carcinoma. J Med Life 2009, 2(2):211-218.
206. Lazar-Molnar E, Hegyesi H, Toth S, Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12(6):547-554. (Pubitemid 30453481)
207. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP: Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep 2001, 8(5):955-964. (Pubitemid 33758152)
208. Snarskaia ES, Molochkov VA, Frank GA, Zavalishina LA: Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin. Arkhiv Patologii 2005, 67(3):14-16. (Pubitemid 41039764)
209. Lievre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C, Laurent-Puig P, Members of the ANGH group: Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 2006, 6:270.
210. Ricketts C, Zeegers MP, Lubinski J, Maher ER: Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One 2009, 4(6):e6037.
211. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J: Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997, 75(9):1385-1388. (Pubitemid 27179834)
212. Kozhemiakin LA, Bulavin DV, Morozov VI, Osipov EV, Zolotarev DV: Effectiveness of the glutathione s-transferase assay in diagnosing lung cancer. Vopr Onkol 1995, 41(1):33-38. (Pubitemid 26103634)
213. Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P: Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007, 92(2):277-278. (Pubitemid 46852440)
214. Lavender NA, Benford ML, VanCleave TT, Brock GN, Kittles RA, Moore JH, Hein DW, Kidd LC: Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study. BMC Cancer 2009, 9:397.
215. Saadat I, Saadat M: The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia. Cancer Lett 2000, 158(1):43-45. (Pubitemid 30625229)
216. Ovsepian VA, Vinogradova E, Sherstneva ES: Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika 2010, 46(10):1360-1362.
217. Vrana D, Pikhart H, Mohelnikova-Duchonova B, Holcatova I, Strnad R, Slamova A, Schejbalova M, Ryska M, Susova S, Soucek P: The association between glutathione S-transferase gene polymorphisms and pancreatic cancer in a central European Slavonic population. Mutat Res 2009, 680(1-2):78-81.